Medtronic (NYSE:MDT) Gains FDA Approval for Advanced Insulin Sensor in 2025

By Yahoo! Finance   |   3 weeks ago
Medtronic (NYSE:MDT) Gains FDA Approval for Advanced Insulin Sensor in 2025

Medtronic's Simplera Sync sensor FDA approval enhances the MiniMed 780G system, showcasing its tech advancements. Market dynamics impacted its flat share price despite positive news. Analysts project revenue growth, positioning Medtronic for future gains. Keep an eye on competitive pressures and regulatory changes.

Read More

Did you find this insightful?